Phase 2 Epilepsy Trial, Recruiting (NCT06590896)

Phase 2 Epilepsy Trial, Recruiting NCT06590896 Sponsor: Ono Pharmaceutical Co., Ltd. Condition: Epilepsy

Printed from Voxsanity (voxsanity.com.au) — NCT06590896 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Epilepsy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must have fully completed the previous related clinical study called YKP3089C035, run by SK Life Science.

Who may not be able to join:

You left or stopped participating in the previous study (YKP3089C035) early for any reason.
There have been significant changes to your medical history that the study doctor believes could put your safety at risk (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Project Leader, Ono Pharmaceutical Co., Ltd.

Phone: +18665877745(Toll-Free)

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06590896

Sponsor: Ono Pharmaceutical Co., Ltd.

Phase: Phase 2

Status: Recruiting

Condition: Epilepsy

Trial contact: +18665877745(Toll-Free)

More information: https://clinicaltrials.gov/study/NCT06590896

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must have fully completed the previous related clinical study called YKP3089C035, run by SK Life Science.

Who may not be able to join:

You left or stopped participating in the previous study (YKP3089C035) early for any reason.
There have been significant changes to your medical history that the study doctor believes could put your safety at risk (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Ono Pharmaceutical Co., Ltd.

Registry

ClinicalTrials.gov

Start date

4 November 2022

Est. completion

31 January 2027

Where this trial is recruiting

🇯🇵 Japan

Primary endpoints

Incidences of Adverse Events (AEs) and Serious Adverse Events (SAEs); Urinalysis(pH); Urinalysis(Specific Gravity); Urinalysis(Protein); Urinalysis(Glucose); Urinalysis(Ketone); Urinalysis(Bilirubin); Urinalysis(Blood); Urinalysis(Nitrite); Urinalysis(Urobilinogen); Urinalysis( Microscopic Examination); Liver function tests(total protein); Liver function tests(albumin); Liver function tests(total bilirubin); Liver function tests(aspartate transaminase); Liver function tests(alanine aminotransferase); Liver function tests(alkaline phosphatase); Liver function tests(gamma-glutamyl transferase);...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov